Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Viral hepatitis C prognosis is related to the presence of a fibrosis and to the risk of developing cirrhosis or hepatic cancer. The study will evaluate the efficacy of prazosin to make hepatic fibrosis regress, in patients with chronic hepatitis C and severe fibrosis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
• Treatments: Interferon alpha-2; Interferon-alpha; Interferons; Peginterferon alfa-2b; Prazosin; Ribavirin

Criteria

Inclusion Criteria:

• Chronic viral hepatitis C, genotype 1 or 4

• Fibrosis F3 or F3-F4, assessed by the scoring Metavir system

• Initial treatment against HCV

Exclusion Criteria:

• Psychiatric pathology

• Alcool consummation

• Pregnancy or plan of pregnancy

• Breastfeeding